Sabin Shrestha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sabin Shrestha has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Basu Dev Pandey
DEJIMA Infectious Disease Research Alliance, Nagasaki University, Nagasaki, Japan
4 shared publications - Kouichi Morita
Department of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
4 shared publications - Mya Myat Ngwe Tun
Department of Tropical Viral Vaccine Development, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan
4 shared publications - Sandesh Rimal
Department of Microbiology, Faculty of Medicine, Kindai University, Sakai 590-0197, Osaka, Japan
4 shared publications - Shyam Prakash Dumre
Central Department of Microbiology, Tribhuvan University, Kathmandu, Nepal
4 shared publications - Anjana Kharbuja
Central Department of Microbiology, Tribhuvan University, Kathmandu 44601, Nepal
3 shared publications
Latest Publications
- Open Access
- 8 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (41)
Disulfide cross-linked redox-sensitive peptide condensates are efficient cell delivery vehicles of molecular cargo
Biomolecular condensates (BCs) are phase-separated viscoelastic hubs within demixed solutions enriched in proteins and nucleic acids. Such condensates, also called membraneless organelles, are increasingly observed in cells and serve as transient hubs for spatial organization and compartmentalization of biomolecules. Along with the transiency of formation and dissolution, their ability to sequester molecules has inspired us to develop BCs as potential vehicles to transport and deliver molecular cargo. We recently reported the design of disulfide bond cross-linked phase-separating peptide (PSP) condensates that spontaneously dissolve in reducing conditions. Based on the premise that the highly reducing cytoplasm could dissolve PSP condensates and release partitioned cargo, here, we demonstrate the ability of PSP condensates to deliver molecular cargo to the cytoplasm of HeLa cells. We show that PSP condensates deliver a variety of cargos that differ in their sizes and chemistries, including small molecules, peptides, GFP (31 kDa), DNA (1.7 kbp), and mRNA. The transfection efficiencies of PSP condensates for delivering DNA and mRNA were also significantly greater than those of a commercial transfection agent. With room to tailor the condensate properties based on cargo and cell types, these results showcase the potential of disulfide-cross-linked PSPs as effective and customizable cellular delivery vehicles, filling a critical demand gap for such delivery systems.
- 8 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (41)
Open AccessDisulfide cross-linked redox-sensitive peptide condensates are efficient cell delivery vehicles of molecular cargo
Biomolecular condensates (BCs) are phase-separated viscoelastic hubs within demixed solutions enriched in proteins and nucleic acids. Such condensates, also called membraneless organelles, are increasingly observed in cells and serve as transient hubs for spatial organization and compartmentalization of biomolecules. Along with the transiency of formation and dissolution, their ability to sequester molecules has inspired us to develop BCs as potential vehicles to transport and deliver molecular cargo. We recently reported the design of disulfide bond cross-linked phase-separating peptide (PSP) condensates that spontaneously dissolve in reducing conditions. Based on the premise that the highly reducing cytoplasm could dissolve PSP condensates and release partitioned cargo, here, we demonstrate the ability of PSP condensates to deliver molecular cargo to the cytoplasm of HeLa cells. We show that PSP condensates deliver a variety of cargos that differ in their sizes and chemistries, including small molecules, peptides, GFP (31 kDa), DNA (1.7 kbp), and mRNA. The transfection efficiencies of PSP condensates for delivering DNA and mRNA were also significantly greater than those of a commercial transfection agent. With room to tailor the condensate properties based on cargo and cell types, these results showcase the potential of disulfide-cross-linked PSPs as effective and customizable cellular delivery vehicles, filling a critical demand gap for such delivery systems.
- 29 August 2025
- Published by Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis in Japanese Journal of Infectious Diseases
- Vol. 78 (3-4) , 143-146
Seroprevalence of Hepatitis A and E virus Antibodies in Dhanusha, Madhesh Province, Nepal
Hepatitis A virus (HAV) and hepatitis E virus (HEV) are thought to have similar routes of transmission and epidemiology in developing countries. This study investigated the seroprevalences of these pathogens among healthy individuals in the Dhanusha district of Madesh Province, Nepal. Ninety serum samples collected between 2022 and 2023 were analyzed by enzyme-linked immunosorbent assay to detect immunoglobulin (Ig)G antibodies against HAV and HEV. Individuals (median age, 23 years; range, 1–45 years) were sorted into five age groups: 1–10, 11–20, 21–30, 31–40 and 41–45 years. Prevalences of HAV and HEV IgGs were 96.7% and 13.3%, respectively. All age groups showed very high positivity rates for HAV antibodies. In contrast, HEV infection rates were extremely low in children, and rapidly increased in adults >31 years old. No significant correlation was found between HAV and HEV seropositivity. Additional studies including other areas in Nepal are required for nationwide sero-surveillance against HAV and HEV.
- 29 August 2025
- Published by Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis in Japanese Journal of Infectious Diseases
- Vol. 78 (3-4) , 143-146
Seroprevalence of Hepatitis A and E virus Antibodies in Dhanusha, Madhesh Province, Nepal
Hepatitis A virus (HAV) and hepatitis E virus (HEV) are thought to have similar routes of transmission and epidemiology in developing countries. This study investigated the seroprevalences of these pathogens among healthy individuals in the Dhanusha district of Madesh Province, Nepal. Ninety serum samples collected between 2022 and 2023 were analyzed by enzyme-linked immunosorbent assay to detect immunoglobulin (Ig)G antibodies against HAV and HEV. Individuals (median age, 23 years; range, 1–45 years) were sorted into five age groups: 1–10, 11–20, 21–30, 31–40 and 41–45 years. Prevalences of HAV and HEV IgGs were 96.7% and 13.3%, respectively. All age groups showed very high positivity rates for HAV antibodies. In contrast, HEV infection rates were extremely low in children, and rapidly increased in adults >31 years old. No significant correlation was found between HAV and HEV seropositivity. Additional studies including other areas in Nepal are required for nationwide sero-surveillance against HAV and HEV.
- Open Access
- 6 August 2025
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 113 (2) , 378-381
Detection of Dengue and Chikungunya Viruses in Mosquitoes from Nepal
: The dengue virus (DENV) and chikungunya virus (CHIKV) infection present with similar symptoms and are transmitted by Aedes mosquitoes. Until now, there have been no reported cases of DENV and CHIKV being detected in mosquitoes in Nepal. This study identified circulating arboviruses from mosquitoes collected in the capital city Kathmandu, and Dhading, Bhaktapur, and Lalitpur districts of Central Nepal in 2023. Of 105 Aedes pooled samples, 16 (15.2%) were positive for DENV, and six (5.7%) were positive for CHIKV by quantitative real-time polymerase chain reaction. DENV-2 was the most common serotype (11.4%), aligning with recent outbreaks in Nepal in 2023, followed by DENV-3 and DENV-4 (1.9% each). To the best of our knowledge, our study is the first report to detect DENV and CHIKV in Aedes mosquitoes circulating in Nepal. This study highlights the need for mosquito surveillance to prevent future outbreaks of mosquito-borne diseases in Nepal.
- 6 August 2025
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 113 (2) , 378-381
Open AccessDetection of Dengue and Chikungunya Viruses in Mosquitoes from Nepal
: The dengue virus (DENV) and chikungunya virus (CHIKV) infection present with similar symptoms and are transmitted by Aedes mosquitoes. Until now, there have been no reported cases of DENV and CHIKV being detected in mosquitoes in Nepal. This study identified circulating arboviruses from mosquitoes collected in the capital city Kathmandu, and Dhading, Bhaktapur, and Lalitpur districts of Central Nepal in 2023. Of 105 Aedes pooled samples, 16 (15.2%) were positive for DENV, and six (5.7%) were positive for CHIKV by quantitative real-time polymerase chain reaction. DENV-2 was the most common serotype (11.4%), aligning with recent outbreaks in Nepal in 2023, followed by DENV-3 and DENV-4 (1.9% each). To the best of our knowledge, our study is the first report to detect DENV and CHIKV in Aedes mosquitoes circulating in Nepal. This study highlights the need for mosquito surveillance to prevent future outbreaks of mosquito-borne diseases in Nepal.
- Open Access
Emergence of Dengue Virus Serotypes 1 and 3 in Mahottari and Adjacent Areas of Southern Nepal
Dengue has been a serious public health concern in Nepal since the past few years, with concurrent big outbreaks occurring in 2022–2024. This cross-sectional study was conducted among febrile patients visiting hospitals in Mahottari district in southern Nepal. A total of 2141 dengue-suspected patients were investigated by routine laboratory assays and serological and molecular techniques, including real-time quantitative polymerase chain reaction (RT-qPCR). Among them, 455 (21.3%) were confirmed as dengue cases. The majority of dengue cases (435, 95.6%) had a primary dengue infection. The total bilirubin level was significantly higher in secondary dengue infection than in primary (p = 0.032). The major dengue virus (DENV) serotypes responsible for this outbreak were DENV-1 (45.5%) and DENV-2 (40.9%), while 13.6% patients had DENV-3 infection. DENV-3 infection showed a significantly higher viral load (median: 7.71 Log10 copies/mL; range: 6.48–7.94) compared to DENV-1 (6.72 Log10 copies/mL; 5.49–7.17) and DENV-2 (4.76 Log10 copies/mL; 2.32–6.96). Adult patients exhibited a significantly higher viral load than children (p = 0.035). NS1- and IgM-positive as well as admitted patients had a higher viral load (p < 0.05). Co-circulation of multiple serotypes (DENV-1, -2, -3) was confirmed with the first introduction of DENV-1 and DENV-3 in Mahottari and surrounding areas in the 2023 outbreak. Identification of the circulating DENV serotypes is crucial to understanding the epidemiological trend and dynamics of population immunity. These findings underscore the need of nation-wide integrated surveillance, including genomic data generation, in Nepal for disease control, prevention, and potential vaccine implication.
Open AccessEmergence of Dengue Virus Serotypes 1 and 3 in Mahottari and Adjacent Areas of Southern Nepal
Dengue has been a serious public health concern in Nepal since the past few years, with concurrent big outbreaks occurring in 2022–2024. This cross-sectional study was conducted among febrile patients visiting hospitals in Mahottari district in southern Nepal. A total of 2141 dengue-suspected patients were investigated by routine laboratory assays and serological and molecular techniques, including real-time quantitative polymerase chain reaction (RT-qPCR). Among them, 455 (21.3%) were confirmed as dengue cases. The majority of dengue cases (435, 95.6%) had a primary dengue infection. The total bilirubin level was significantly higher in secondary dengue infection than in primary (p = 0.032). The major dengue virus (DENV) serotypes responsible for this outbreak were DENV-1 (45.5%) and DENV-2 (40.9%), while 13.6% patients had DENV-3 infection. DENV-3 infection showed a significantly higher viral load (median: 7.71 Log10 copies/mL; range: 6.48–7.94) compared to DENV-1 (6.72 Log10 copies/mL; 5.49–7.17) and DENV-2 (4.76 Log10 copies/mL; 2.32–6.96). Adult patients exhibited a significantly higher viral load than children (p = 0.035). NS1- and IgM-positive as well as admitted patients had a higher viral load (p < 0.05). Co-circulation of multiple serotypes (DENV-1, -2, -3) was confirmed with the first introduction of DENV-1 and DENV-3 in Mahottari and surrounding areas in the 2023 outbreak. Identification of the circulating DENV serotypes is crucial to understanding the epidemiological trend and dynamics of population immunity. These findings underscore the need of nation-wide integrated surveillance, including genomic data generation, in Nepal for disease control, prevention, and potential vaccine implication.
- Top Cited PapersOpen Access
A Comprehensive Review of the Neglected and Emerging Oropouche Virus
Oropouche virus (OROV) is a neglected and emerging arbovirus that infects humans and animals in South and Central America. OROV is primarily transmitted to humans through the bites of infected midges and possibly some mosquitoes. It is the causative agent of Oropouche fever, which has high morbidity but low mortality rates in humans. The disease manifests in humans as high fever, headache, myalgia, arthralgia, photophobia, and, in some cases, meningitis and encephalitis. Additionally, a recent report suggests that OROV may cause fetal death, miscarriage, and microcephaly in newborns when women are infected during pregnancy, similar to the issues caused by the Zika virus (ZIKV), another mosquito-borne disease in the same regions. OROV was first reported in the mid-20th century in the Amazon basin. Since then, over 30 epidemics and more than 500,000 infection cases have been reported. The actual case numbers may be much higher due to frequent misdiagnosis, as OROV infection presents similar clinical symptoms to other co-circulating viruses, such as dengue virus (DENV), chikungunya virus (CHIKV), ZIKV, and West Nile virus (WNV). Due to climate change, increased travel, and urbanization, OROV infections have occurred at an increasing pace and have spread to new regions, with the potential to reach North America. According to the World Health Organization (WHO), over 10,000 cases were reported in 2024, including in areas where it was not previously detected. There is an urgent need to develop vaccines, antivirals, and specific diagnostic tools for OROV diseases. However, little is known about this surging virus, and no specific treatments or vaccines are available. In this article, we review the most recent progress in understanding virology, transmission, pathogenesis, diagnosis, host–vector dynamics, and antiviral vaccine development for OROV, and provide implications for future research directions.
Top Cited PapersOpen AccessA Comprehensive Review of the Neglected and Emerging Oropouche Virus
Oropouche virus (OROV) is a neglected and emerging arbovirus that infects humans and animals in South and Central America. OROV is primarily transmitted to humans through the bites of infected midges and possibly some mosquitoes. It is the causative agent of Oropouche fever, which has high morbidity but low mortality rates in humans. The disease manifests in humans as high fever, headache, myalgia, arthralgia, photophobia, and, in some cases, meningitis and encephalitis. Additionally, a recent report suggests that OROV may cause fetal death, miscarriage, and microcephaly in newborns when women are infected during pregnancy, similar to the issues caused by the Zika virus (ZIKV), another mosquito-borne disease in the same regions. OROV was first reported in the mid-20th century in the Amazon basin. Since then, over 30 epidemics and more than 500,000 infection cases have been reported. The actual case numbers may be much higher due to frequent misdiagnosis, as OROV infection presents similar clinical symptoms to other co-circulating viruses, such as dengue virus (DENV), chikungunya virus (CHIKV), ZIKV, and West Nile virus (WNV). Due to climate change, increased travel, and urbanization, OROV infections have occurred at an increasing pace and have spread to new regions, with the potential to reach North America. According to the World Health Organization (WHO), over 10,000 cases were reported in 2024, including in areas where it was not previously detected. There is an urgent need to develop vaccines, antivirals, and specific diagnostic tools for OROV diseases. However, little is known about this surging virus, and no specific treatments or vaccines are available. In this article, we review the most recent progress in understanding virology, transmission, pathogenesis, diagnosis, host–vector dynamics, and antiviral vaccine development for OROV, and provide implications for future research directions.
- Open Access
- 24 October 2024
- Published by Elsevier in Medical Reports
- Vol. 8
A challenge to clinical management: A case of expanded dengue syndrome co-infection with dengue 1 and dengue 3 serotypes in Nepal
- 24 October 2024
- Published by Elsevier in Medical Reports
- Vol. 8
Open AccessA challenge to clinical management: A case of expanded dengue syndrome co-infection with dengue 1 and dengue 3 serotypes in Nepal
- Open Access
Molecular and Entomological Characterization of 2023 Dengue Outbreak in Dhading District, Central Nepal
In 2023, Nepal faced its second largest dengue outbreak ever, following a record-breaking number of dengue cases in 2022, characterized by the expansion of infections into areas of higher altitudes. However, the characteristics of the 2023 circulating dengue virus (DENV) and the vector density remain poorly understood. Therefore, we performed DENV serotyping, clinical and laboratory assessment, and entomological analysis of the 2023 outbreak in central Nepal. A total of 396 fever cases in Dhading hospital suspected of being DENV positive were enrolled, and blood samples were collected and tested by different techniques including PCR. Of these, 278 (70.2%) had confirmed DENV infection. Multiple serotypes (DENV-1, -2, and -3) were detected. DENV-2 (97.5%) re-emerged after six years in Dhading while DENV-3 was identified for the first time. Dengue inpatients had significantly higher frequency of anorexia, myalgia, rash, diarrhea, nausea, vomiting, abdominal pain, and thrombocytopenia (p < 0.05). In this area, Aedes mosquitoes largely predominated (90.7%) with the majority being A. aegypti (60.7%). We also found high levels of Aedes index (20.0%) and container index (16.7%). We confirmed multiple DENV serotype circulation with serotype re-emergence and new serotype introduction, and high vector density in 2023. These findings call for the urgent initiation and scaling up of DENV molecular surveillance in human and mosquito populations for dengue control and prevention in Nepal.
Open AccessMolecular and Entomological Characterization of 2023 Dengue Outbreak in Dhading District, Central Nepal
In 2023, Nepal faced its second largest dengue outbreak ever, following a record-breaking number of dengue cases in 2022, characterized by the expansion of infections into areas of higher altitudes. However, the characteristics of the 2023 circulating dengue virus (DENV) and the vector density remain poorly understood. Therefore, we performed DENV serotyping, clinical and laboratory assessment, and entomological analysis of the 2023 outbreak in central Nepal. A total of 396 fever cases in Dhading hospital suspected of being DENV positive were enrolled, and blood samples were collected and tested by different techniques including PCR. Of these, 278 (70.2%) had confirmed DENV infection. Multiple serotypes (DENV-1, -2, and -3) were detected. DENV-2 (97.5%) re-emerged after six years in Dhading while DENV-3 was identified for the first time. Dengue inpatients had significantly higher frequency of anorexia, myalgia, rash, diarrhea, nausea, vomiting, abdominal pain, and thrombocytopenia (p < 0.05). In this area, Aedes mosquitoes largely predominated (90.7%) with the majority being A. aegypti (60.7%). We also found high levels of Aedes index (20.0%) and container index (16.7%). We confirmed multiple DENV serotype circulation with serotype re-emergence and new serotype introduction, and high vector density in 2023. These findings call for the urgent initiation and scaling up of DENV molecular surveillance in human and mosquito populations for dengue control and prevention in Nepal.
- Open Access
Co-Circulation of Dengue Virus Serotypes 1, 2, and 3 during the 2022 Dengue Outbreak in Nepal: A Cross-Sectional Study
The largest dengue outbreak in the history of Nepal occurred in 2022, with a significant number of casualties. It affected all 77 districts, with the nation’s capital, Kathmandu (altitude 1300 m), being the hardest hit. However, the molecular epidemiology of this outbreak, including the dengue virus (DENV) serotype(s) responsible for this epidemic, remain unknown. Here, we report the epidemic trends, clinico-laboratory features, and virus serotypes and their viral load profiles that are associated with this outbreak in Nepal. Dengue-suspected febrile patients were investigated by routine laboratory, serological, and molecular tools, including a real-time quantitative polymerase chain reaction (qRT-PCR). Of the 538 dengue-suspected patients enrolled, 401 (74.5%) were diagnosed with dengue. Among these dengue cases, 129 (32.2%) patients who required hospital admission had significant associations with myalgia, rash, diarrhea, retro-orbital pain, bleeding, and abdominal pain. DENV-1, -2, and -3 were identified during the 2022 epidemic, with a predominance of DENV-1 (57.1%) and DENV-3 (32.1%), exhibiting a new serotype addition. We found that multiple serotypes circulated in 2022, with a higher frequency of hospitalizations, more severe dengue, and more deaths than in the past. Therefore, precise mapping of dengue and other related infections through integrated disease surveillance, evaluation of the dynamics of population-level immunity and virus evolution should be the urgent plans of action for evidence-based policy-making for dengue control and prevention in the country.
Open AccessCo-Circulation of Dengue Virus Serotypes 1, 2, and 3 during the 2022 Dengue Outbreak in Nepal: A Cross-Sectional Study
The largest dengue outbreak in the history of Nepal occurred in 2022, with a significant number of casualties. It affected all 77 districts, with the nation’s capital, Kathmandu (altitude 1300 m), being the hardest hit. However, the molecular epidemiology of this outbreak, including the dengue virus (DENV) serotype(s) responsible for this epidemic, remain unknown. Here, we report the epidemic trends, clinico-laboratory features, and virus serotypes and their viral load profiles that are associated with this outbreak in Nepal. Dengue-suspected febrile patients were investigated by routine laboratory, serological, and molecular tools, including a real-time quantitative polymerase chain reaction (qRT-PCR). Of the 538 dengue-suspected patients enrolled, 401 (74.5%) were diagnosed with dengue. Among these dengue cases, 129 (32.2%) patients who required hospital admission had significant associations with myalgia, rash, diarrhea, retro-orbital pain, bleeding, and abdominal pain. DENV-1, -2, and -3 were identified during the 2022 epidemic, with a predominance of DENV-1 (57.1%) and DENV-3 (32.1%), exhibiting a new serotype addition. We found that multiple serotypes circulated in 2022, with a higher frequency of hospitalizations, more severe dengue, and more deaths than in the past. Therefore, precise mapping of dengue and other related infections through integrated disease surveillance, evaluation of the dynamics of population-level immunity and virus evolution should be the urgent plans of action for evidence-based policy-making for dengue control and prevention in the country.
- Open Access
- 31 December 2022
- Published by Nepal Journals Online (JOL) in Tribhuvan University Journal of Microbiology
- p. 35-42
Antibiotic resistance pattern of Methicillin-resistant Staphylococcus aureus in asymptomatic prisoners of Kathmandu valley
bjectives: The purpose of this study was to determine the prevalence of methicillin-resistant Staphylococcus aureus and its antimicrobial resistance among the prisoners within the prisons of Kathmandu valley. Methods: A total of 320 nasal samples were collected from the prisoners. S. aureus was confirmed by using standard microbiological techniques including culture and biochemical tests. MRSA was confirmed using cefoxitin disc and antimicrobial susceptibility testing was performed by Kirby-Bauer disc diffusion method results were interpreted according to the guidelines of Clinical Laboratory Standard Institute (CLSI). Results: Out of 320 samples, 41 (12.82%) isolates were confirmed S. aureus and 8 (19.51%) of them were screened as MRSA positive. Highest percentage of MRSA was found in the samples collected from Nakhu prison 6 (75%) followed by Central prison 1 (12.5%) and Juvenile Correctional Home 1 (12.5%). Majority of the of MRSA isolates (62.5%) were also found to be multiple drug-resistant strains. All of the MRSA (100%) were sensitive towards linezolid and resistant towards ciprofloxacin. Conclusion: The presence of methicillin-resistant S. aureus among the prisoners indicates the emergence of drug resistance in a vulnerable population which may lead to hazardous disease breakouts in the prison and even in the community after their release. Regular monitoring and its minimization should be done in order to control its dissemination.
- 31 December 2022
- Published by Nepal Journals Online (JOL) in Tribhuvan University Journal of Microbiology
- p. 35-42
Open AccessAntibiotic resistance pattern of Methicillin-resistant Staphylococcus aureus in asymptomatic prisoners of Kathmandu valley
bjectives: The purpose of this study was to determine the prevalence of methicillin-resistant Staphylococcus aureus and its antimicrobial resistance among the prisoners within the prisons of Kathmandu valley. Methods: A total of 320 nasal samples were collected from the prisoners. S. aureus was confirmed by using standard microbiological techniques including culture and biochemical tests. MRSA was confirmed using cefoxitin disc and antimicrobial susceptibility testing was performed by Kirby-Bauer disc diffusion method results were interpreted according to the guidelines of Clinical Laboratory Standard Institute (CLSI). Results: Out of 320 samples, 41 (12.82%) isolates were confirmed S. aureus and 8 (19.51%) of them were screened as MRSA positive. Highest percentage of MRSA was found in the samples collected from Nakhu prison 6 (75%) followed by Central prison 1 (12.5%) and Juvenile Correctional Home 1 (12.5%). Majority of the of MRSA isolates (62.5%) were also found to be multiple drug-resistant strains. All of the MRSA (100%) were sensitive towards linezolid and resistant towards ciprofloxacin. Conclusion: The presence of methicillin-resistant S. aureus among the prisoners indicates the emergence of drug resistance in a vulnerable population which may lead to hazardous disease breakouts in the prison and even in the community after their release. Regular monitoring and its minimization should be done in order to control its dissemination.